chr16-2085312-GAGA-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PM4_SupportingPP5_Very_Strong
The NM_000548.5(TSC2):c.4655_4657delAAG(p.Glu1552del) variant causes a disruptive inframe deletion change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 33)
Consequence
TSC2
NM_000548.5 disruptive_inframe_deletion
NM_000548.5 disruptive_inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 6.58
Genes affected
TSC2 (HGNC:12363): (TSC complex subunit 2) This gene is a tumor suppressor gene that encodes the growth inhibitory protein tuberin. Tuberin interacts with hamartin to form the TSC protein complex which functions in the control of cell growth. This TSC protein complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 13 ACMG points.
PM1
In a domain Rap-GAP (size 227) in uniprot entity TSC2_HUMAN there are 284 pathogenic changes around while only 47 benign (86%) in NM_000548.5
PM2
Very rare variant in population databases, with high coverage;
PM4
Nonframeshift variant in NON repetitive region in NM_000548.5. Strenght limited to Supporting due to length of the change: 1aa.
PP5
Variant 16-2085312-GAGA-G is Pathogenic according to our data. Variant chr16-2085312-GAGA-G is described in ClinVar as [Pathogenic]. Clinvar id is 49310.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-2085312-GAGA-G is described in Lovd as [Pathogenic]. Variant chr16-2085312-GAGA-G is described in Lovd as [Likely_pathogenic]. Variant chr16-2085312-GAGA-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TSC2 | NM_000548.5 | c.4655_4657delAAG | p.Glu1552del | disruptive_inframe_deletion | 36/42 | ENST00000219476.9 | NP_000539.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TSC2 | ENST00000219476.9 | c.4655_4657delAAG | p.Glu1552del | disruptive_inframe_deletion | 36/42 | 5 | NM_000548.5 | ENSP00000219476.3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:5Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Tuberous sclerosis 2 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Division of Genomic Medicine, Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University | Jul 10, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 26, 2023 | Experimental studies have shown that this variant affects TSC2 function (PMID: 22903760). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. ClinVar contains an entry for this variant (Variation ID: 49310). This variant is also known as 4654_4656delGAA. This variant has been observed in individual(s) with tuberous sclerosis (PMID: 11112665, 22903760, 23389244). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This variant, c.4655_4657del, results in the deletion of 1 amino acid(s) of the TSC2 protein (p.Glu1552del), but otherwise preserves the integrity of the reading frame. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
TSC2-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 18, 2024 | The TSC2 c.4655_4657delAAG variant is predicted to result in an in-frame deletion (p.Glu1552del). This variant was reported in patients with tuberous sclerosis (Dabora et al. 2001. PubMed ID: 11112665; Table S1, van Eeghen et al. 2012. PubMed ID: 22867869; Table S1, Togi et al. 2022. PubMed ID: 36232477; Niida et al. 2013. PubMed ID: 23389244; Roberts et al. 2002. PubMed ID: 12136241). In vitro studies found this variant reduced protein function (Hoogeveen-Westerveld et al. 2012. PubMed ID: 22903760). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 17, 2021 | The c.4655_4657delAAG variant (also known as p.E1552del) is located in coding exon 35 of the TSC2 gene. This variant results from an in-frame AAG deletion at nucleotide positions 4655 to 4657. This results in the in-frame deletion of a glutamic acid at codon 1552. This alteration has been identified in numerous individuals with clinical features associated with tuberous sclerosis (Roberts PS et al. Hum Genet, 2002 Jul;111:96-101; Niida Y et al. J Hum Genet, 2013 Apr;58:216-25). An in vitro functional assay showed that this variant is deleterious compared to wild-type (Hoogeveen-Westerveld M et al. Hum Mutat 2013 Jan;34(1):167-75). Of note, this alteration is also described in the literature as c.4654_4656delGAA. This amino acid position is well conserved in available vertebrate species. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Tuberous sclerosis syndrome Other:1
not provided, no classification provided | curation | Tuberous sclerosis database (TSC2) | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at